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Abstract
Background: VCAM-1 represents one of the most important adhesion molecule involved in the transmigration of
blood leukocytes across the blood-brain barrier (BBB) that is an essential step in the pathogenesis of MS. Several
evidences have suggested the potential therapeutic value of cannabinoids (CBs) in the treatment of MS and their
experimental models. However, the effects of endocannabinoids on VCAM-1 regulation are poorly understood. In
the present study we investigated the effects of anandamide (AEA) in the regulation of VCAM-1 expression
induced by Theiler’s virus (TMEV) infection of brain endothelial cells using in vitro and in vivo approaches.
Methods: i) in vitro: VCAM-1 was measured by ELISA in supernatants of brain endothelial cells infected with TMEV
and subjected to AEA and/or cannabinoid receptors antagonist treatment. To evaluate the functional effect of
VCAM-1 modulation we developed a blood brain barrier model based on a system of astrocytes and brain
endothelial cells co-culture. ii) in vivo: CB1 receptor deficient mice (Cnr1
-/-) infected with TMEV were treated with
the AEA uptake inhibitor UCM-707 for three days. VCAM-1 expression and microglial reactivity were evaluated by
immunohistochemistry.
Results: Anandamide-induced inhibition of VCAM-1 expression in brain endothelial cell cultures was mediated by
activation of CB1 receptors. The study of leukocyte transmigration confirmed the functional relevance of VCAM-1
inhibition by AEA. In vivo approaches also showed that the inhibition of AEA uptake reduced the expression of
brain VCAM-1 in response to TMEV infection. Although a decreased expression of VCAM-1 by UCM-707 was
observed in both, wild type and CB1 receptor deficient mice (Cnr1
-/-), the magnitude of VCAM-1 inhibition was
significantly higher in the wild type mice. Interestingly, Cnr1-/- mice showed enhanced microglial reactivity and
VCAM-1 expression following TMEV infection, indicating that the lack of CB1 receptor exacerbated
neuroinflammation.
Conclusions: Our results suggest that CB1 receptor dependent VCAM-1 inhibition is a novel mechanism for AEA-
reduced leukocyte transmigration and contribute to a better understanding of the mechanisms underlying the
beneficial role of endocannabinoid system in the Theiler’s virus model of MS.
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Background
Vascular cell adhesion molecule-1 (VCAM-1), an
endothelial receptor belonging to the immunoglobulin
superfamily is a key player in leukocyte extravasation in
multiple sclerosis (MS) [[1]; rev [2]]. High levels of this
molecule have been found in chronic active lesions as
well as in blood and CSF from MS patients [3] whereas it
was hardly detectable in normal brain tissue [4]. Blockade
of the interaction of VCAM-1 with its ligand, the very
late antigen-4 (VLA-4), has been tested in animal models
and also in clinical trials in relapsing remitting MS
patients showing a significant reduction of relapse rates
and MRI activity which led to the development of a new
drug for MS treatment (natalizumab) [5-7]. Theiler’s
murine encephalomyelitis virus-induced demyelinating
disease (TMEV-IDD) is a well characterized murine
model of human MS, which closely resembles the
chronic and progressive clinical form of the disease [8].
The endocannabinoid system (ECS), consists of endo-
genous ligands (AEA and 2-AG) and congeners, target
receptors, synthesis (NAPE-PLD; DAG lipase), and
degradation enzymes (FAAH, MAGL) and proteins
involved in their transport, and intracellular trafficking
[9]. Increasing evidence suggests the involvement of the
ECS in both the inflammatory and the neurodegenerative
processes associated to MS and other neurodegenerative
diseases [rev [10,11]]. Both AEA and 2-AG possess anti-
inflammatory and neuroprotective properties against
harmful insults [12-16]. Controversial changes in the
levels of endocannabinoids have been reported in MS
and in animal models of the disease [11]. It has been sug-
gested that the increased endocannabinoid tone might
respond to an attempt to limit brain damage thus having
a neuroprotective effect [13,15] whereas its decrease
would be related to pathogenic processes [17]. The thera-
peutic potential of exogenous CBs, but also the pharma-
cological modulation of the ECS in animal models of
multiple sclerosis has been related to their neuroprotec-
tive and anti-inflammatory activity [18-22]. A diminished
number of leukocyte infiltrates into the CNS has been
shown to occur in the EAE model by administering the
synthetic cannabinoid WIN 5,212-2 [23]. In the TMEV-
IDD model we showed that WIN 5,212-2 at the time of
virus infection inhibited brain VCAM-1 expression and
interfered with later disease onset [24]. However, there is
still little information about the effects of endocannabi-
noids, and in particular of AEA, on the mechanisms
involved in the control of leukocyte trafficking. Advance
in the knowledge of VCAM-1 regulation by endocannabi-
noids may be useful to clarify the mechanisms underlying
the efficacy of endocannabinoid-bases therapies. In this
report, we have addressed the role of AEA in regulating
1) VCAM-1 expression in brain endothelial cells infected
with TMEV and the possible receptors involved by using
antagonists of the classical cannabinoid receptors, CB1
and CB2, antagonists of the vanilloid receptor TRPV1
and inhibitors of PPAR-g receptors; 2) leukocyte transmi-
gration in a model of BBB; and 3) in vivo brain VCAM-1
expression and microglial reactivity in TMEV-infected
mice.
Methods
Animal and Theiler’s virus inoculation
We used female Biozzi ABH and ABH mice lacking the
CB1 receptor (Cnr1) gene, susceptible to TMEV-IDD
development, gently gifted by Dr. Baker (University Col-
lege London). Mice were maintained on food and water
ad libitum in a 12 hours dark-light cycle. Four-to six
week-old mice were inoculated intracerebrally in the right
cerebral hemisphere with 106 plaque forming units (PFU)
of Daniel’s (DA) TMEV strain, in 30 μl of Dulbecco’s
modified Eagle’s medium supplemented with 10% of fetal
calf serum (FCS) as previously described [21,25]. Handling
of animals was performed in compliance with the guide-
lines of animal care set by the European Union (86/609/
EEC) and the Spanish regulations (BOE67/8509-12;
BOE1201/2005) on the use and care of laboratory animals,
and approved by the local Animal Care and Ethics Com-
mittee of the CSIC.
Experimental procedure
At the time of TMEV infection, the mice were treated
with UCM-707 (3 mg/kg, injected i.p.) twice a day (morn-
ing and afternoon) for 3 consecutive days or appropriate
vehicle (5% BSA and 0.2% DMSO in phosphate-buffered
saline). This dose was chosen on the basis of previous stu-
dies in our laboratory [18].
Tissue processing and immunohistochemistry
Animal tissue was processed as previously described [24].
Briefly, mice were perfused transcardially with saline.
Brains were fixed in 4% paraformaldehyde in 0.1 M PB,
washed in 0.1 M PB, cryoprotected with a 7%, 15% and
later 30% solution of sucrose in 0.1 M PB and frozen at
-80°C until used. Free-floating coronal brain sections
(30 μm thick) were processed as described previously
[24] to visualize the adhesion molecule VCAM-1 (anti-
VCAM-1 antibody; BD Pharmingen, San Diego, CA) and
microglia (Iba-1 antibody; Wako Chemical Pure Industry,
GmbH). Immunostaining was visualized with the corre-
sponding secondary antibodies conjugated with avidin-
peroxidase (Dako, Barcelona, Spain) and revealed with
the choromogen 3.3’ diaminobenzidine tetrahydrochlor-
ide (DAB; Sigma-Aldrich Inc, St. Louis, MO, USA) fol-
lowed by counterstaining with toluidine blue. In all cases
specificity of staining was confirmed by omitting the
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primary antibody. To quantify VCAM-1 expression fluor-
escence secondary antibody was used and six confocal
immunofluorescence microphotograps per level were
analyzed using the Image J software designed by National
Institutes of Health. Results are presented as intensity of
staining per vessel in case of VCAM-1 study or percen-
tage of area occupied by CD11b+ staining per field in
case of microglial analysis.
Cell cultures
b.End5: Murine brain endothelial cells (b.End5) which
are recognized to present brain endothelium like prop-
erties were obtained from European Collection of Cell
Cultures (UK). This cell model is an appropriate choice
to study blood-brain barrier function [26-28]. The cells
were grown in Dulbeccos’s Modified Eagle’s Medium
supplemented with 10% heat inactivated fetal bovine
serum (FBS); 1% nonessential aminoacid, 1% sodium
pyruvate and 1% antibiotic penicillin and streptomycin
(all from Gibco, Scotland, UK) and were maintained
under standard cell culture conditions at 37°C and 5%
CO2. One hour before experiments, cells were subjected
to restricted conditions (1% FBS). In order to assess the
possible receptors involved in the effects of AEA, one
hour before the treatment with AEA (10 μM) and
TMEV (2 × 105 pfu), cells were pre-treated with the
cannabinoid receptors antagonists SR141716A (CB1, 1
μM); AM630 (CB2, 1 μM); capsazepine (TRPV1, 10 μM)
or GW9662 (PPARg, 100 nM, 1 μM).
Astrocytes: cell cultures were obtained as previously
described [29]. Forebrains were dissociated mechanically,
filtered through a 150 μm nylon mesh, resuspended in
DMEM containing 10% heat-inactivated FCS, 10% heat-
inactivated FBS and 1% penicillin/streptomycin and plated
on poly-L-lysin-coated (5 μg/ml) 75 cm2 flasks (Nunc,
Wiesbaden, Germany). After 7 days in culture the flasks
were shaken at 260 rpm at 37°C overnight to remove
microglia and oligodendrocytes.
Leukocytes: Lymphatic nodes were homogenized in cold
PBS with the plunger of a syringe, filtered through a
70 μm cell strainer to obtain a single cell suspension, cen-
trifuged for 5 min at 1200 rpm and resuspended in RPMI
supplemented with 10 mM HEPES (pH 7.4), 2 mM gluta-
mine and 10% FCS, b-mercaptoethanol (50 μM).
Adhesion assay
Confluent brain endothelial cell monolayer infected with
TMEV (2 × 105 pfu) and treated with AEA (10 μM) was
subjected or not to the cannabinoid receptors antagonist
by pre-treatment for 1 hour with the CB1 or CB2 selective
receptor antagonist, SR141716A (SR1, 1 μM) or AM630
(1 μM), respectively. After 6 hours, 2.5 × 105 leukocytes
stained with calcein acetoxymethyl ester (AM) (5 μM)
(Sigma-Aldrich Inc, St. Louis, MO, USA) were allowed to
adhere to endothelial monolayer for 20 hours. Lapsed
this time non bound leukocytes were removed, five
microphotographs/field, fluorescence and phase contrast,
were used for counting adhered leukocytes by Meta-
morph software. The assay was performed in triplicate
for each value and was repeated 3 times. Calcein acetoxy-
methyl ester is a vital dye what is membrane permeable
but becomes membrane impermeable and fluorescent
when cleaved by intracellular sterases.
Blood brain barrier model
Blood brain barrier model was performed as described
previously [30] with modifications. Briefly, transwell filters
(surface area 6.4 mm; pore size, 8 μm; BD Falcon™
Cell Culture Inserts) were coated with colagen type I
(50 μg/ml; BD Falcon) and fibronectine (50 μg/ml; Invitro-
gen, Barcelona, Spain). Astrocytes (5 × 104 cell/well) were
allowed to adhere to the bottom of the filter for 10 min-
utes in DMEM with 10% FBS, 10% FCS and 1% penicillin/
streptomycin. Contamination of adherent astrocytes on
the bottom of the well was avoided. After 24 hours, brain
endothelial cells (b.End5) were seeded on the top of the fil-
ter at a density of 5 × 104 cell/well in DMEM with 10%
FBS, 1% non-essential aminoacid, 1% sodium pyruvate and
1% penicillin/streptomycin. We consider that BBB was
established when transendothelial electrical resistance was
close to 200Ω/cm2 [30]. Once confluent, endothelial cells
were infected with TMEV (2 × 105 pfu) and treated with
AEA (10 μM). To study the involvement of cannabinoid
receptor, cells were pre-treated with the CB1 or CB2 recep-
tors antagonist, SR1 (1 μM) or AM630 (1 μM) respec-
tively. Following stimulation for 6 hours, 2.5 × 105
leukocytes were added on the top of the insert for
20 hours. The entire transmigrating cell populations pre-
sent in the bottom chamber were collected and counted
by using a hemocytometer. For schematic illustration of
the BBB model see additional file 1A and additional file 2.
Permeability assay
Permeability assay was performed as described [31].
Briefly, after rinsed in phenol-red-free DMEM the top
and the bottom of the filter, 400 μl of 10% FBS/phenol-
red-free DMEM and 200 μl of 0.45% albumin conju-
gated to Evan’s blue dye were added to the bottom and
the top of the well, respectively and incubated at 37°C
for 30 min. Absorbance of the bottom medium was read
at 620 nm [see Additional file 1B].
Immunocytochemistry
To visualize the tight junction zonula occludens-1 (ZO-1)
in the blood brain barrier model, cells were fixed with 4%
paraformaldehyde, washed with PBS and incubated over-
night at 4°C with the primary antibody (ZO-1, Zymed
Laboratorioes, Carlsbad, CA) in PBS containing 5% NGS
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and 0,1 Triton X-100. After washing with PBS, cells were
incubated for 1 h at RT with secondary anti-rabbit anti-
body IgGs, conjugated with Alexa 488 (Molecular Probes,
Eugene, OR, USA) washed with PBS and mounted on
glass slides with fluorescent mounting medium. In all
cases, specificity of staining was confirmed by omitting
the primary antibody [see Additional file 1C].
ELISA
Soluble fraction VCAM-1 (sVCAM-1) content in
endothelial cells supernatants was measured by solid
phase sandwich ELISA, using a monoclonal antibody
specific for mouse sVCAM-1 (R & D Systems Inc., MN,
USA), according to the manufacturer’s instructions. The
assay sensitivity was 30 pg/ml.
Statistical analysis
All results are presented as mean ± SEM. For in vitro
experiments the n value corresponds at least to three
independent experiments; with triplicate determinations
in each experiment. One-way ANOVA, followed by a
post hoc Tukey’s multiple comparison tests was used to
examine the statistical significance of in vitro assays.
Repeated measure test and post hoc Duncan test was
used to analyze the statistical significance of VCAM-1
and CD11b studies. p values < 0.05 were considered
significant.
Results
Anandamide inhibits VCAM-1 induced by TMEV in brain
endothelial cells by CB1 receptors
The endothelial blood brain barrier protects the CNS from
the changing environment in both physiologic and patho-
logic conditions. Previous work in our lab has demon-
strated that sVCAM-1 is constitutively expressed on b.
End5 cells and increased by TMEV infection [24]. We first
analyzed the effect of AEA on the production of VCAM-1
by TMEV-infected brain endothelial cells. Dose response
studies of AEA on sVCAM-1 production showed that
10 μM was the most effective dose to prevent the expres-
sion of VCAM-1 induced by TMEV at 20 hours postinfec-
tion (Figure 1A). AEA also inhibited VCAM-1 expression
in resting cells (data not shown). Down-regulation of
VCAM-1 induced by AEA (10 μM) was partially reversed
by the addition of the CB1 receptor antagonist,
SR141716A (SR1) but not by the CB2 receptor antagonist
AM630 (Figure 1B). The doses used for CB antagonists
were 1 μM on the basis of their capability for antagonizing
CB effects in our previous work. To examine if vanilloid
receptors expressed in brain endothelial cells [32] were
involved in AEA inhibition of VCAM-1 we pretreated the
cells with capsazepine (10 μM). As shown in Figure 1C,
the blockade of vanilloid receptors did not modify
the inhibitory effect of AEA on VCAM-1 expression. In
addition we explored the role of PPARg receptors as it has
been described to mediate some of the actions of AEA
[reviewed by [33]]. In our study the treatment with the
inhibitor of PPARg, GW9662 (at nanomolar and micro-
molar doses) did not prevent AEA-induced VCAM-1 inhi-
bition (Figure 1D). In conclusion, AEA-induced inhibition
of VCAM-1 in brain endothelial cells implies the activa-
tion of CB1 receptors.
Anandamide limits leukocyte migration through a blood
brain barrier model by a mechanism involving CB1
receptors
VCAM-1 is critically involved in leukocyte transmigration
into the CNS. Therefore, our next step was to assess the
functional relevance of AEA-induced VCAM-1 inhibition
in leukocyte transmigration. First, we showed that leuko-
cyte adhesion to TMEV-infected endothelium was signifi-
cantly increased (p < 0.01) in comparison to cell adhering
to resting cell monolayer. Importantly, the treatment with
AEA (10 μM), at the time of virus infection diminished
leukocyte adhesion (p < 0.01) (Figure 2A). In agreement
with the involvement of CB1 receptors in AEA-induced
VCAM-1 inhibition, the pretreatment with the CB1 recep-
tor antagonist (SR1), but not with the CB2 antagonist
(AM630), reversed the inhibitory effect of AEA on leuko-
cyte adhesion (Figure 2A). Quantification is presented as a
ratio of number of leukocyte adhered to the endothelial
cell monolayer in each group normalized to control group
(Figure 2B).
Next, we analyzed whether the effect of AEA on the
adhesion of leukocytes interferes on leukocyte transmigra-
tion through the BBB model. As expected TMEV-infection
of brain endothelial cells increased the number of leuko-
cytes crossed the BBB model referred to control (Figure
2C). Accordingly to our results in the experiments of leu-
kocytes adhesion the treatment of endothelial cells with
AEA (10 μM) diminished leukocyte crossing by a mechan-
ism that involves CB1 receptors. Figure 2D shows the
quantification data on the number of leukocytes that cross
the BBB model.
The increased anandamide tone inhibits VCAM-1
expression in Theiler’s virus-infected mice
On the basis of our in vitro results, we next analyze the
effect of the pharmacological modulation of the AEA
tone on VCAM-1 response against TMEV infection in
vivo, using wild type and CB1 knockout mice (Cnr1
-/-).
Accordingly to other studies [24], VCAM-1 expression
was not detected, by immunohistochemistry, in the
brains of sham animals in both type of mice, Cnr1+/+ or
Cnr1-/-. The intracranial injection of TMEV induced the
expression of VCAM-1 in the ipsilateral cerebral cortex
surrounding blood vessels close to the site of injection
in both type of mice, Cnr1+/+ as well as Cnr1-/- mice
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(Figure 3A). Corroborating our in vitro findings, the
treatment with the inhibitor of AEA uptake UCM-707
induced a significant reduction of VCAM-1 expression
in TMEV-infected mice (Figure 3A). Although, UCM-
707 decreased VCAM-1 expression in Cnr1+/+ and
Cnr1-/- mice, quantification analysis (Figure 3B) revealed
that the degree of VCAM-1 reduction in the ipsilateral
cerebral cortex of Cnr1+/+ mice was significantly higher
than that observed in Cnr1-/- (p < 0.05). This observa-
tion suggests the participation of CB1 receptors in the
effects of UCM-707 treatment. Additionally, when we
analysed the contralateral hemisphere (Figure 3C) we
found that only mice lacking CB1 receptors showed
increased VCAM-1 expression in the vasculature in
response to TMEV that was significantly inhibited by
the treatment with UCM-707 as revealed the quantifica-
tion of staining intensity (Figure 3D).
The increased anandamide tone limits microglial
activation in mice infected with Theiler’s virus
The intracranial injection of Theiler’s virus induced an
increase of microglia with reactive morphology in the
cerebral cortex at the level of infection (medium level)
but only in the ipsilateral infected hemisphere (Figure
4A). Interestingly, the microglial response was exacer-
bated in Cnr1-/- mice (Figure 4B), now extending from
prefrontal cortex (rostral level) to hippocampal level
(caudal level). When we analyzed the contralateral hemi-
sphere we found that microglial cells did not show reac-
tive morphology at the three brain levels examined in
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μM) or AM630 (1 μM); (C) the vanilloid receptor antagonist capsazepine (10 μM); (D) the PPARg receptor antagonist GW9662 (100 nM and 1 μM).
Results show the means ± SEM from three independent experiments done in triplicate. (**p < 0,01 vs. vehicle; ##p < 0.01 vs. TMEV+vehicle; ++p
< 0.01 vs. TMEV+AEA, ANOVA followed by Tuckey’s test).
Mestre et al. Journal of Neuroinflammation 2011, 8:102
http://www.jneuroinflammation.com/content/8/1/102
Page 5 of 13
Control TMEV TMEV+AEA TMEV+AEA+SR1
TMEV+AEA
+AM630
A
2
3
4
5
6B ** **
##
Fo
ld
+
0
1
SR1
1PM
AM630
1PM
AEA (10PM)
vehiclevehicle
TMEV (2x105pfu)
vehicle
Control TMEV TMEV+AEA TMEV+AEA+SR1
TMEV+AEA
+AM630
C
40000 ** ++D
0
10000
20000
30000
le
uk
oc
yt
es
SR1 AM630vehiclevehicle vehicle
##
&
1PM 1PM
AEA (10PM)
TMEV (2x105pfu)
Figure 2 AEA limits leukocyte adhesion to TMEV stimulated brain endothelial cells and leukocyte transmigration through in vitro BBB
by CB1 involvement. Brain endothelial cell monolayer were stimulated with a combination of TMEV (2 × 10
5 pfu), AEA (10 μM), SR1 (1 μM) or
AM630 (1 μM) for 6 hours. After that, 2.5 × 105 leukocytes stained with AM-calcein (5 μM) were added to the endothelial culture for 20 hours.
(A) Representative immunofluorescence microphotographs of the leukocytes stained with AM-calcein adhered to the brain endothelial cell
monolayer in each case and phase contrast microphotographs of brain endothelial monolayer merged with immunofluorescence
microphotographs of AM-calcein stained leukocytes bring out with arrows. Scale bar 100 μm. (B) Quantification of leukocytes adhered to brain
endothelial monolayer in each case normalized to control group (n = 6). (**p < 0.01 vs. vehicle; ##p < 0.01 vs. TMEV; +p < 0.05 vs. TMEV+AEA,
ANOVA followed by Tuckey’s tests). (C) TMEV (2 × 105 pfu), plus AEA (10 μM), or plus SR1 (1 μM) or AM630 (1 μM) were added to the upper side
of the insert (endothelial culture) and IL1-b (10 ng/ml) was added to the bottom side (astrocyte culture) for 6 hours. 2.5 × 105 leukocytes were
added to the upper side of the insert for 20 hours and representative phase contrast microphotographs of leukocytes crossed to bottom side of
the insert were taken. (D) Quantification of leukocytes in the bottom side of the insert after 20 hours of experiment. (**p < 0.01 vs. vehicle; ##p
< 0.01 vs. TMEV+vehicle; ++p < 0.01 vs. TMEV+AEA; &p < 0.05 vs. TMEV+AEA+SR1, ANOVA followed by Tuckey’s test; n = 6).
Mestre et al. Journal of Neuroinflammation 2011, 8:102
http://www.jneuroinflammation.com/content/8/1/102
Page 6 of 13
the wild type mice as well as in Cnr1-/- mice. Therefore,
in response to TMEV infection, activation of microglial
cells only occurred in the ipsilateral hemisphere. Quan-
tification analysis of percentage of area occupied by
microglia per field was summarized in Figure 4C.
The treatment with UCM-707 significantly (p < 0.01)
reduced the presence of microglia with reactive mor-
phology in Cnr1+/+ mice (Figure 5B) at the medium
level close to the site of injection (Figure 5A). Cerebral
cortex sections from Cnr1-/- mice showed a tendency
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TMEV-infected and Sham mice were treated with UCM-707 (3 mg/kg) or the corresponding vehicle (n = 3 for each group) immediately after
virus infection for three consecutive days. Analysis were performed using representative microphotographs of coronal brain sections (30 μm) of
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toward diminishing microglia reactivity but without
reaching statistical significance (p = 0,07; Figure 5C).
The analysis of the contralateral hemispheres didn’t
reveal the presence of microglia with reactive morphol-
ogy (data not shown).
Discussion
The ECS has been suggested to contribute to the main-
tenance of homeostasis between the immune and the
nervous systems [34,35]. Besides, the pharmacological
activation of ECS is emerging as a potential therapeutic
strategy for neurodegenerative diseases including multi-
ple sclerosis [rev [10,36]]. Mechanisms underlying the
beneficial effects of CBs on MS are not fully clarified;
however, anti-inflammatory and/or neuroprotective
actions seem to be involved [37]. Leukocyte migration
into the CNS is widely recognized as a pivotal event in
the development of MS in which adhesion molecules
like VCAM-1 are critically involved and emerge as mar-
ker of endothelial activity [rev [2,7]].
The notion that restriction of immune cells traffic into
the CNS by CBs could represent a novel mechanism to
suppress brain immune reactivity was first suggested by
two laboratories in both, TMEV-IDD and EAE models by
using the synthetic agonist WIN 55,212-2 [21,23]. In the
present study we show that the endocannabinoid, AEA
inhibits the expression of VCAM-1 in TMEV-infected
brain endothelial cells resulting in reduced leukocyte adhe-
sion and crossing through an in vitro model of BBB. In the
TMEV-IDD model, cumulative evidence suggests that
TMEV may enter the CNS by infection of cerebrovascular
endothelial cells. Thus, infection of endothelial cells might
represent one of the first events in the pathogenesis of
TMEV-induced demyelination. The persistence of TMEV
in cloned mouse cerebrovascular endothelial cells appears
to support this concept [38]. Pioneering studies on
TMEV-IDD showed that adhesion molecules play a criti-
cal role in leukocyte extravasation [39] pointing out the
interest of a reduction of VCAM-1 expression by AEA.
CB1 and CB2 receptors were expressed in b.End5 as well
Cnr1+/+ Cnr1-/-A B
ipsilateral contralateral ipsilateral contralateral
TMEV
Cnr1+/+ Cnr1-/-
ipsilateral contralateral Ipsilateral contralateral
Rostrallevel 13,773± 0,592++ 12,013± 0,489 20,028± 1,257## 16,956± 0,913
Mediallevel 25,277± 1,403** 13,223± 0,788 21,341± 0,958## 17,151± 1,007
Caudal level 16 621 ± 1 465++ 15 909 ± 2 327 19 657 ± 1 120# 16 320 ± 0 796
C
 ,  , ,  , ,  , ,  ,
Figure 4 CB1 deletion exacerbates microglial response against TMEV infection. Coronal brain sections (30 μm) were obtained from Cnr1
+/+
TMEV-infected mice (A) or Cnr1-/- TMEV-infected mice (B), stained for CD11b with Iba-1 antibody and counterstained with toluidine blue (n = 3
for each group). To perform the analysis of microglia phenotype morphology brain tissue was studied in both hemispheres and at rostral, medial
and caudal levels. (C) Quantification of percentage of area occupied by microglia per field is represented. Scale bar is 50 μm. **p < 0.01 vs.
contralateral (Cnr1+/+); #p < 0.05 vs. contralateral (Cnr1-/-); ##p < 0.01 vs. contralateral (Cnr1-/-); ++p < 0.01 vs. medial level (Cnr1+/+).
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Figure 5 The treatment with UCM-707 decreases microglia reactivity in TMEV-infected mice. Study with Cnr1+/+ and Cnr1-/- mice. Both
TMEV-infected and Sham mice from both strains (Cnr1+/+ and Cnr1-/-) were treated with UCM-707 (3 mg/kg) or the corresponding vehicle (n =
3 for each group) immediately after the virus infection for three consecutive days. (A) Coronal brain section level for the analysis of CD11b+
expression. (B) Representative micrographs of ipsilateral cerebral cortex in sham, TMEV-infected plus vehicle or TMEV infected plus UCM-707 from
Cnr1+/+ or Cnr1-/- mice. (C) Quantification of percentage of area occupied by microglia per field is represented. Scale bar is 50 μm. **p < 0.01 vs
Sham (Cnr1+/+); ++p < 0.01 vs. TMEV+vehicle (Cnr1+/+); ##p < 0.01 vs Sham (Cnr1-/-); &p = 0.07 vs. TMEV+vehicle (Cnr1-/-).
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as in primary cultures of murine brain endothelial cells
[40]. Most of the effects of CBs are mediated by their spe-
cific receptors CB1 and CB2 that are asymmetrically dis-
tributed in the BBB. CB1 receptor is mainly located at the
luminal side while CB2 receptors are on the abluminal side
of the endothelium [41,19]. In our study, VCAM-1 sup-
pression by AEA in brain endothelial cells was mainly
mediated by the activation of CB1 receptors. Most impor-
tantly, AEA-induced inhibition of leukocyte adhesion and
crossing through the BBB also involved CB1 receptors
accordingly to the specific distribution of this type of
receptors in the BBB. In agreement with our observations,
studies on HIV-1 Gp120-effects in brain microvascular
endothelial cells have shown that CB1 based synthetic CBs
prevented monocyte transmigration across a human
model of BBB [42]. Although CB1, CB2 [40] and TRPV1
[32] receptors are expressed in murine brain endothelial
cells, our results ruled out the involvement of CB2 and
TRPV1 receptors in AEA-induced inhibition of VCAM-1.
Differential expression of CB2 receptors and NAPE-PLD
(the major enzyme associated with synthesis of AEA) in
cerebral endothelium at different stages of MS has been
recently reported [43]. In the above study, increased CB2
receptor staining was associated with BBB disruption in
active plaques from MS tissue samples, suggesting a role
for endothelial CB2 in the protection and/or repair of BBB
injury. However, previous studies of MS brain tissue did
not find endothelial expression of CB2 [44,45]. In TMEV-
infected brain endothelial cells the possibility that AEA
activates PPAR-g receptors [33] to suppress VCAM-1 can
be also discharged despite the fact that PPARs agonists
prevent the interaction of leukocytes with stimulated
endothelium [46].
The majority of studies on AEA actions in endothelial
cells have focused on its vasodilator and hypotensive
activity and there were discrepancies on the type of
receptor implicated, probably due to differences between
peripheral and brain endothelial cells [47]. Using mouse
cerebral endothelial cells and consistent with our results,
AEA-induced increased COX-2 expression involves the
activation of CB1 receptors [48].
Although alterations in the ECS during the course of MS
have been suggested to represent a protective physiological
strategy [13,18,49,50] the role of endocannabinoids in MS
remains uncertain. While most of studies on ECS and MS
focused on established disease, understanding the role of
endocannabinoids during the induction phase would be an
important point as exacerbated leukocyte trafficking into
the CNS represents a key stage in the disease. Therefore,
here, we investigated the role of CB1 receptors and the
effects of the inhibitor of AEA uptake, UCM-707, on
VCAM-1 expression in wild type and CB1 knockout mice
(Cnr1-/-) during the early phases of TMEV-IDD. Intracra-
nial infection with TMEV induced the expression of
VCAM-1 in surrounding blood vessels close to the site of
injection in Cnr1+/+ as well as in Cnr1-/- mice whereas
VCAM-1 was not detected in brains of sham animal in
both type of mice accordingly to other studies [4,24]. The
treatment with UCM-707 resulted in down-regulation of
VCAM-1 expression in both type of mice. However, the
degree of inhibition of VCAM-1 in the ipsilateral cerebral
cortex of Cnr1+/+ mice was significantly higher than that
observed in Cnr1-/- mice supporting the involvement of
CB1 receptors and corroborating our in vitro results. In
addition, the analysis of the contralateral hemisphere
showed increased VCAM-1 expression only in the vascula-
ture of Cnr1-/- mice that was inhibited by UCM-707.
Thus, our in vivo data confirm the importance of CB1
receptors but, suggest that besides CB1 receptors, addi-
tional mechanisms are contributing to the effects of
UCM-707 on VCAM-1 inhibition. It is difficult to have
the overall picture of what is happening as consequence of
increasing AEA tone under the conditions of our study
due to the multiple cellular targets for AEA actions on the
responses to TMEV infection. Nevertheless, we have
shown here that AEA by targeting brain endothelial cells
may interfere with leukocyte recruitment across the BBB
through the inhibition of VCAM-1.
As suggested in the cardiovascular endothelium [51,52]
in the brain endothelium AEA and other endocannabi-
noids like 2-AG, would be synthetized and released from a
nearby source such as astrocytes [53], microglia [54] and
even from the own endothelial cells to regulate the
response of brain endothelium to different stimuli as we
observed in the case of TMEV. The observation that
NAPE-PLD expression is elevated on blood vessels and in
reactive astrocytes distributed closely around them sug-
gests the synthesis of AEA by brain endothelium in MS
[43]. In other models of brain injury 2-AG has been
shown to be released and to reduce BBB damage [14,55].
Additionally, endocannabinoids may control brain
innate immunity in MS by acting in different CNS cell
types such as astrocytes and microglial besides immune
cells [rev [56]]. Activating or inhibiting the innate immune
response influences the development of TMEV-IDD [57].
In this line, AEA enhances IL-6 production in astrocytes
infected with TMEV by a CB1 receptor-mediated pathway
[58] and in a more recent work AEA modulates TMEV-
induced IL-12, IL-23 and IL-10 in microglia by activating
CB2 receptors [59].
An important finding of the present study is that the
lack of CB1 receptor leads to an exacerbation of microglial
response to TMEV infection in the ipsilateral hemisphere.
Thus, microglial activation was observed from prefrontal
cortex to hippocampal levels instead of maintaining it
exclusively in the area close to the injection site. Currently,
we unknown the meaning of the extensive microglial acti-
vation in Cnr1-/- mice, but it is likely to be associated with
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the facilitation of spreading viral antigens as microglia/
macrophages are an important virus reservoir [60]. In line
with a protective role of CB1 receptors previous studies
have reported that CB1-knockout mice develop more
severe CREAE [61,62]. Moreover, recent studies reveal
that repeat polymorphism of the Cnr1 gene could repre-
sent a genetic risk factor for both the primary progressive
[63] and relapsing-remitting form of MS [64].
Conclusions
In summary, mechanisms underlying the decreased cel-
lular infiltration on the CNS by CBs in animal models
of MS are not yet clear but the present study showed
that anandamide was effective in reducing endothelial
VCAM-1 expression and BBB permeability via CB1
receptors. More relevant is that the inhibitor of ananda-
mide uptake, UCM-707 reduced VCAM expression in
TMEV infected mice with the participation of CB1
receptors. Available data from MS patients subjected to
success natalizumab therapy showed downregulation of
sVCAM-1 which is considered a good biomarker of
endothelial activity [7]. The inhibition of VCAM-1
expression in cerebral vasculature by anandamide pro-
vides a new mechanism that may explain the therapeutic
action of increased anandamide tone in neuroinflamma-
tory diseases like MS.
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